



ACTION Study Group
Institute of Cardiology
Pitié-Salpêtrière Hospital
Paris - France



1 mois de DAPT pour tous apres DES

“Oui”

G. Montalescot

Dr. Montalescot reports research Grants to the Institution or Consulting/Lecture Fees from ADIR, Amgen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women's Hospital, Cardiovascular Research Foundation, Celladon, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fédération Française de Cardiologie, Fondazione Anna Maria Sechi per il Cuore, Gilead, ICAN, Janssen, Lead-Up, Menarini, Medtronic, MSD, Pfizer, Sanofi-Aventis, The Medicines Company, TIMI Study Group, WebMD.

Dernière génération DES + coronarien stable
= DAPT < 12 mois?

Oui biensur!

Duration of DAPT : Guidelines

Guideline Recommendations on Duration of Dual Antiplatelet Therapy Post-Stenting

Patient Subpopulation	U.S. Guidelines	European Guidelines	U.K. NICE Guidelines	Australian Guidelines
Stent (BMS or DES) in patients with ACS	At least 12 months (COR I, LOE: B). Longer durations may be considered in patients with DES (COR IIb, LOE: C)	Up to 12 months (COR I, LOE: A)	Up to 12 months*	12 months (COR I, LOE: B) †
BMS in non-ACS	At least 1 month (minimum 2 weeks if increased bleeding risk, ideally up to 12 months) (COR I, LOE: B)	At least 1 month (COR I, LOE: A)	According to device-specific instructions*	Endorses U.S. guideline*
DES in non-ACS	At least 12 months (COR I, LOE: B)	6 months (COR I, LOE: B)	At least 12 months*	Endorses U.S. guideline*
Secondary prevention	May be considered (COR IIb, LOE: B)	Selected patients at high risk of ischemic events*	Not recommended beyond 12 months*	Consider in patients with recurrent ischemic events*

ACS = acute coronary syndrome(s); BMS = bare-metal stent(s); COR = class of recommendation; DES = drug-eluting stent(s); LOE = Level of Evidence
 *No COR or LOE provided. †COR and LOE adapted from Australian National Health and Medical Research Council guidelines

Duration of DAPT \leq 6months after DES

FIGURE 2 MI in the Meta-Analysis of L-DAPT Versus S-DAPT for Studies With S-DAPT for \leq 6 Months





FIGURE 3 Major Bleeding in the Meta-Analysis of S-DAPT Versus L-DAPT for Studies With S-DAPT for \leq 6 Months



Dernière génération DES + coronarien stable
= DAPT ≤6 mois

Oui biensur!

Duration of DAPT of 3 months after DES

FIGURE 2 MI in the Meta-Analysis of L-DAPT Versus S-DAPT for Studies With S-DAPT for ≤ 6 Months






FIGURE 3 Major Bleeding in the Meta-Analysis of S-DAPT Versus L-DAPT for Studies With S-DAPT for ≤ 6 Months



Dernière génération DES + coronarien stable
= DAPT <6 mois, même si haut risque

Oui biensur!

Diabète




Dernière génération DES + coronarien stable
= DAPT 1 mois


Oui c'est possible!

SORT OUT VIII Trial Design

Randomized, prospective, multicenter, all-comer, two-arm, non-inferiority trial, N=2800




Strut Coverage Rate (SEM)




COBRA PzF



Synergy



Xience



Duration of DAPT : Guidelines

Guideline Recommendations on Duration of Dual Antiplatelet Therapy Post-Stenting

Patient Subpopulation	U.S. Guidelines	European Guidelines	U.K. NICE Guidelines	Australian Guidelines
Stent (BMS or DES) in patients with ACS	At least 12 months (COR I, LOE: B). Longer durations may be considered in patients with DES (COR IIb, LOE: C)	Up to 12 months (COR I, LOE: A)	Up to 12 months*	12 months (COR I, LOE: B) †
BMS in non-ACS	At least 1 month (minimum 2 weeks if increased bleeding risk, ideally up to 12 months) (COR I, LOE: B)	At least 1 month (COR I, LOE: A)	According to device-specific instructions*	Endorses U.S. guideline*
DES in non-ACS	At least 12 months (COR I, LOE: B)	6 months (COR I, LOE: B)	At least 12 months*	Endorses U.S. guideline*
Secondary prevention	May be considered (COR IIb, LOE: B)	Selected patients at high risk of ischemic events*	Not recommended beyond 12 months*	Consider in patients with recurrent ischemic events*


ACS = acute coronary syndrome(s); BMS = bare-metal stent(s); COR = class of recommendation; DES = drug-eluting stent(s); LOE = Level of Evidence

*No COR or LOE provided. †COR and LOE adapted from Australian National Health and Medical Research Council guidelines

1-month DAPT after DES


ZEUS study (n=1606)

Death, MI or TVR



LEADERS-FREE study (n=2466)

Cardiac death, MI or stent thrombosis



Valgimigli et al. JACC 2015;65:805-815

Urban P et al. N Engl J Med 2015;373:2038-2047


...and more ongoing RCTs with short DAPT: MASTER-DAPT (1 month), SENIOR (1 month), COBRA-REDUCE (15 days), ...

Dernière génération DES + SCA

= DAPT < 6 mois


Oui c'est possible!

PLATO, ticagrelor in Hs Tn negative patients



hsTnT negL at entry

<14	16517 (3.1%)	12496 (2.4%)	1.40 (0.66-2.97)	0.042
14-134	86404 (13.1%)	75829 (11.0%)	1.11 (0.85-1.51)	
135-494	59528 (11.2%)	77568 (13.6%)	0.76 (0.56-1.07)	
≥495	77803 (12.8%)	115596 (19.3%)	0.65 (0.49-0.87)	



Wallentin L et al. Circulation 2014;129:293-303



Consider these ACS patients like SCAD patients

≤ 6-month DAPT in ACS/DES patients

Table 2 Endpoints in studies evaluating abbreviated duration of dual antiplatelet therapy (6 months or less) after stenting in populations having a majority of acute coronary syndrome patients


	Stent thrombosis		MACE		Major bleeding	
	S-DAPT	L-DAPT	S-DAPT	L-DAPT	S-DAPT	L-DAPT
PRODIGY	15 (1.5)	13 (1.3)	98 (10.0)	100 (10.1)	6 (0.6)	16 (1.6)
RESET	2 (0.2)	3 (0.3)	8 (0.8)	11 (1.3)	5 (0.5)	10 (1)
EXCELLENT	6 (0.9)	1 (0.1)	56 (8.0)	60 (8.5)	4 (0.6)	10 (1.4)
Total n/N (%)	23/2532 (0.9)	17/2529 (0.7)	162/2532 (6.4)	171/2529 (6.8)	15/2532 (0.6)	36/2529 (1.4)
	0.9%	0.7%	6.4%	6.8%	0.6%	1.4%

Montalescot G, Sabatine MS.
Eur Heart J. 2016;37(4):344-52.

Dernière génération DES + SCA
= DAPT 1 mois


Oui c'est possible!

ZEUS Trial: 63% ACS, 47% MI HBR sub-population



No. at Risk				
BMS	392	373	359	351
E-ZES	356	335	320	314

LEADERS-Free:HBR Patients ACS Substudy



No. at Risk				
BMS	295	272	260	247
DCS	308	294	284	279

Ariotti S, et al. JACC CI 2016;9(5):426-36
*stent randomized/ 30 days DAPT

Naber, et al. Eur Heart J 2016 (epub)
**stent randomized/ 30 days DAPT

Conclusions

- Short DAPT after stenting (last generation DES), both in stable CAD and ACS, is a valid option, in particular if bleeding risk is increased
- Short can be as short as 1 month!
- In other words, the current recommendations of 6-12 months DAPT need to be challenged!